KLRS — Kalaris Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation To Allovir’s Posoleucel For Prevention Of Multiple Life-Threatening Infections From Six Viruses In Allogeneic Hematopoietic Cell Transplant Patients
Brief: Allovir Initiates Phase 3 Registrational Study Of Posoleucel For Prevention Of Life-Threatening Viral Infections From Six Common Viruses In High-Risk Cell Transplant Patients
U.S. RESEARCH ROUNDUP-Ambarella, Carpenter Technology, Morphic Holding
Allovir Inc reports results for the quarter ended in December - Earnings Summary
Brief: AlloVir Reports Full-Year 2021 Financial Results And 2022 Outlook
Allovir Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation To AlloVir’s Posoleucel For The Treatment Of Adenovirus (AdV) Infections In Adults And Children Post-Allogeneic Stem Cell Transplantation
U.S. RESEARCH ROUNDUP-Embark Technology, Innovage Holding, IRhythm Technologies
Brief: AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study At 63rd American Society Of Hematology Annual Meeting
U.S. RESEARCH ROUNDUP-Acutus Medical, Lordstown Motors, Walmart
Allovir Inc reports results for the quarter ended in September - Earnings Summary
U.S. RESEARCH ROUNDUP-Btrs Holdings, Fair Isaac, Monmouth Real Estate Investment
Brief: Allovir Reports Third Quarter 2021 Financial Results
Brief: FDA Grants Orphan Drug Designation (ODD) To AlloVir’s Posoleucel For The Treatment of Virus-Associated Hemorrhagic Cystitis
Allovir Inc reports results for the quarter ended in June - Earnings Summary
Brief: Allovir Inc Files For Potential Mixed Shelf Offering
Brief: Allovir Reports Q2 Results
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Biomea Fusion, Tyson Foods
Allovir Inc reports results for the quarter ended in March - Earnings Summary